Abstracts Archive - Page 980 of 2425 - ACR Meeting Abstracts

Abstract Number: 385 • 2019 ACR/ARP Annual Meeting
Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Sang Wan Chung¹, So-Yun Lee ¹, Sang-Hoon Lee ¹, Seung-Jae Hong ¹ and Yeon-Ah Lee ¹, ¹School of Medicine, Kyung Hee University, seoul, Republic of Korea
Background/Purpose: The connective tissue diseases (CTD) are a group of rheumatologic diseases characterized by inflammation and immune-mediated organ damage including interstitial lung disease (ILD). The…
Abstract Number: 386 • 2019 ACR/ARP Annual Meeting
Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Sarah Ringsted¹ and Marcia Friedman ¹, ¹Oregon Health and Science University, Portland, OR
Background/Purpose: Idiopathic granulomatous mastitis (IGM) is an inflammatory breast disease occurring primarily in young to middle-aged women (1, 2). IGM typically presents with a tender,…
Abstract Number: 387 • 2019 ACR/ARP Annual Meeting
Early Mortality in IgG4-Related Disease
Rachel Wallwork¹, Tyler Harkness ¹, Xiaoqing Fu ¹, Cory Perugino ¹, Hyon K. Choi ², John Stone ³ and Zachary Wallace ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder characterized by tumefactive lesions that can occur in nearly any organ or anatomic site. Manifestations can include…
Abstract Number: 388 • 2019 ACR/ARP Annual Meeting
Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity
Alain Meyer¹, Yves Troyanov ², Julie Drouin ³, Josiane Bourre-Tessier ⁴, Genevieve Oligny-Longpre ⁵, Océane Landon-Cardinal ⁶, Baptiste Hervier ⁷, Sabrina Hoa ⁸, Anne-Marie Mansour ⁹, Eric Rich ⁴, Jean-Richard Goulet ⁴, Sandra Chartrand ¹⁰, Marie Hudson ¹¹, Jessica Nehme ⁹, Jean-Paul Makhzoum ¹², Farah Zarka ⁹, Sara Hussein ¹³, Vincent Morin ¹⁴, Edith Villeneuve ¹⁵, Jean-Pierre Raynauld ¹⁶, Marianne Landry ¹⁷, Erin O'Ferrall ¹⁸, Jose Ferreira ¹⁹, Benjamin Ellezam ²⁰, Jason Karamchandani ¹⁸, Sandrine Larue ²¹, Rami Massie ¹⁸, Catherine Isabelle ²¹, isabelle Deschênes ⁵, Valérie Leclair ²², Helene Couture ²³, Ira Targoff ²⁴, Marvin Fritzler ²⁵ and Jean-Luc Senecal ⁴, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, QC, Canada, ⁴Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁵Hôpital du Haut-Richelieu, Saint-Jean-sur-Richelieu, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Hopital Pitie-Salpetriere, Paris, France, ⁸University of Montreal, Montreal, QC, Canada, ⁹Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁰Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ¹²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Centre hospitalier regional de Lanaudiere, Saint-Charles-Borromée, QC, Canada, ¹⁴Universite Laval, Quebec, QC, Canada, ¹⁵Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁶Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁷Hôpital LaSalle, Montreal, QC, Canada, ¹⁸Montreal Neurological Institute, Montreal, QC, Canada, ¹⁹Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, ²⁰Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ²¹Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada, ²²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ²³Hôpital Enfant-Jesus, Quebec, QC, Canada, ²⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-HMGCR myopathy has recently been defined as a subset of immune-mediated necrotizing myopathies characterized by proximal muscle weakness, elevated CK levels and the presence…
Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Alain Meyer¹, Valérie Leclair ², Océane Landon-Cardinal ³, Benjamin Ellezam ⁴, Julie D'Aoust ⁵, Margherita Giannini ⁶, Bernard Geny ⁶, Laurent Arnaud ⁷, Jacques-Eric Gottenberg ⁸, Jean Sibilia ⁹, Minoru Satoh ¹⁰, Marvin Fritzler ¹¹, Yves Troyanov ¹² and Marie Hudson ¹³, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ⁴Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶CHU de Strasbourg, Strasbourg, France, ⁷Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹CHU Strasbourg, Strasbourg, France, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 391 • 2019 ACR/ARP Annual Meeting
The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle
Joanna Parkes¹, Jessica Boehler ², Ning Li ¹ and Kanneboyina Nagaraju ¹, ¹Binghamton University, Johnson City, NY, ²Solid Biosciences, Boston, MA
Background/Purpose: Rituximab was developed to treat B cell lymphomas but has now been shown to have clinical efficacy in multiple disease conditions (endocrine, neurological, dermatological…
Abstract Number: 392 • 2019 ACR/ARP Annual Meeting
Management of Idiopathic Inflammatory Myopathies Using Intravenous Immunoglobulin Therapy: A Retrospective Cohort Study
Raymond Chu¹, Susan Nahirniak ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies characterized by weakness and inflammation of the muscles. First line therapy typically involves high dose…
Abstract Number: 393 • 2019 ACR/ARP Annual Meeting
Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody
Shinjiro Kaieda¹, Takahisa Gono ², Kenichi Masui ³, Naoshi Nishina ⁴, Shinji Sato ⁵ and Masataka Kuwana ⁶, ¹Department of Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Fukuoka, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ³Department of Anaesthesiology, Show University School of Medicine, Saitama, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan, ⁶Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Surfactant protein D (SP-D) is considered a serum biomarker of various forms of interstitial lung disease (ILD). However, the usefulness of SP-D for prediction…
Abstract Number: 394 • 2019 ACR/ARP Annual Meeting
Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies
Barbora Hermankova ¹, Maja Spiritovic ², Sabina Oreska ³, Hana Storkanova ⁴, Petr Cesak ¹, Katerina Kubinova ⁵, Martin Klein ⁴, Karel Pavelka ³, Ladislav Senolt ³, Herman Mann ³, Jiří Vencovský ³ and Michal Tomcik³, ¹Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammation and weakness of skeletal muscles, pulmonary and articular involvement, which can have a negative impact on…
Abstract Number: 395 • 2019 ACR/ARP Annual Meeting
Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis
Soumyasri Kambhatla¹, Carrie Richardson ², Prasanth Lingamaneni ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: A subset of patients with dermatomyositis may fail to achieve remission despite treatment. Nevertheless, the risk factors for failure to achieve remission in dermatomyositis are largely…
Abstract Number: 396 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry
Jesús Loarce-Martos¹, Carmen Larena ², M. Ángeles Blázquez ¹, Beatriz Joven-Ibáñez ³, Patricia Carreira ³, Julia Martinez Barrio ⁴, Francisco javier López-Longo ⁵, Juan Carlos Lopez-Robledillo ⁶, Raquel Almodovar-Gonzalez ⁷, Irene Llorente ⁸, Eva Tomero-Muriel ⁸, Paloma García-De La Peña ⁹, Henry Moruno ¹⁰, Ana Pérez-Gómez ¹¹, Tatiana Cobo-Ibáñez ¹², María Jesús García De Yébenes ¹³ and Laura Nuño ¹⁴, ¹Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Hospital Universitario Gregorio Marañón, Madrid, ⁶Hospital Niño Jesús, Madrid, Spain, ⁷Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁸Hospital Universitario La Princesa, Madrid, Spain, ⁹Hospital HM San Chinarro, Madrid, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, ¹¹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ¹²Hospital Universitario Infanta Sofía, Madrid, ¹³Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, ¹⁴Hospital Universitario La Paz, Madrid
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are a heterogeneous group of autoimmune diseases affecting children, characterized by symmetric muscular weakness, cutaneous rash and systemic organ…
Abstract Number: 397 • 2019 ACR/ARP Annual Meeting
Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Nozomi Takasugi¹, Yutaro Hayashi ¹, Keisuke Izumi ², Satoshi Hama ³, Misako Konishi ¹, Mari Ushikubo ¹, Yutaka Okano ¹ and Hisaji Ohshima ¹, ¹National Tokyo Medical Center, tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³tokyo medical center, tokyo, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases characterized by proximal myositis. Dysphagia has been reported to develop in 35 to 62% of…
Abstract Number: 398 • 2019 ACR/ARP Annual Meeting
Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Ho SO ¹, Yawen SHEN², Victor Tak Lung WONG ¹, Roy HO ¹ and Xin LU ², ¹Kwong Wah Hospital, Kowloon, Hong Kong, ²China Japan Friendship Hospital, BeiJing, China (People's Republic)
Background/Purpose: Seasonal patterns of disease onset and severity in idiopathic inflammatory myopathies (IIMs) as a whole are conflicting. In recent years, over 10 myositis-specific antibodies…
Abstract Number: 399 • 2019 ACR/ARP Annual Meeting
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Min Shi ², Ira N. Targoff ³, Rodolfo V. Curiel ¹, Frederick W. Miller ⁴ and Lisa G. Rider ⁵, ¹George Washington University, School of Medicine and Health Sciences, Washington, DC, ²Biostatistics&Computational Biology Branch, NIEHS, NIH, Research Triangle Park, NC, ³Arthritis Immunology Section, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NIEHS, NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Published studies suggest seasonal occurrence of disease onset and disease activity in patients with adult idiopathic inflammatory myopathies (IIM).Our objective was to evaluate seasonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].